Iron therapy: Pros and Cons

  • G. Stern
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)


The clinical, neuropathological and experimental evidence for implicating iron in the genesis of certain degenerative diseases of the central nervous system is briefly considered. Even if focal accumulation by decompartmentalisation of iron is a significant event — primarily or secondarily — and an effective selective chelating agent was available, demonstration of efficacy might prove difficult.


Iron Therapy High Iron Content Nervous System Disorder Iron Iron Oxygen Iron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ben-Shachar D, Eshel G, Finberg APM, Youdim MBH (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxy-dopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441–1444PubMedCrossRefGoogle Scholar
  2. Berlin I (1953) The Hedgehog and the Fox. Weidenfeld & NicolsonGoogle Scholar
  3. Braughler JM, Pregenzer JF Chase RL, Ducan LA, Jacobson EJ, McCall JM (1987) Novel 21-aminosteroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem 262: 10438–10440PubMedGoogle Scholar
  4. Cohen RE (1992) Origin of ferro-electricity in perovskite oxides. Nature 358: 136CrossRefGoogle Scholar
  5. Cordy DR (1954) Nigro-pallidal encephelomalacia in horses associated with ingestion of Yellow Star thistle. J Neuropathol Exp Neurol 13: 330–342PubMedCrossRefGoogle Scholar
  6. Drayer BP, Olanow CW, Burger F (1986) High field strength resonance imaging in patients with Parkinson’s disease. Neurology 36: 1: 309–311Google Scholar
  7. Hallervorden J, Spatz H (1922) Eigenartige Erkrankung im extrapyramidalen System mit besonderer Beteiligung des Globus pallidus and der Substantia nigra. Z Ges Neurol Psychiat 79: 254–302CrossRefGoogle Scholar
  8. Hofvander NY (1968) Haematological investigations in Ethiopia with special reference to a high iron intake. Acta Med Scand [Suppl] 494: 1965–1967; Neurology 36 (1): 310Google Scholar
  9. Mettler FA, Stern GM (1962) Observations on the toxic effect of Yellow Star thistle. J Neuropathol Exp Neurol 22: 164–169CrossRefGoogle Scholar
  10. Pick A (1903) Weiterer Beitrag zur Pathologie der Tetanie nebst einer Bemerkung zur Chemie verkalkter Hirngefäße. Neurol 262: 22: 754–756Google Scholar
  11. Pattie TS. The Manuscript Collection. The British Library (personal communication)Google Scholar
  12. Pick A (1903) Weiterer Beitrag zur Pathologie der Tetanie nebst einer Bemerkung zur Chemie verkalkter Hirngefäße. Neurol 262: 22: 754–756Google Scholar
  13. Roy DN, Craig AM, Blythe LL, Kayton RE, Spencer PS (1993) Partial isolation of excitotoxic agents from Yellow Star thistle (Centauria solstialis). A cause of equine nigro-striatal degeneration. Neurodegeneration (in press)Google Scholar
  14. Rybicki BA Johnson CJ, Yuman J, Gorell AM (1993) Parkinson’s disease mortality and the industrial use of heavy metals in Michigan. Mov Disord 8: 1: 87–92PubMedCrossRefGoogle Scholar
  15. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra and zona compacta in parkinsonian brain. J Neurochem 56: 978–982PubMedCrossRefGoogle Scholar
  16. Stern GM (1987) Vitamin E and Parkinson’s disease. Lancet i: 508Google Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • G. Stern
    • 1
  1. 1.Department of Neurology, Middlesex and University College Hospitals School of MedicineUniversity CollegeLondonUK

Personalised recommendations